Pioneering epigenetic treatments for central nervous system disorders
At Flavii, we are committed to making epigenetic treatments available for patients suffering from CNS disorders. We strongly believe we can succeed in meaningfully improving the lives of patients and their families.
ABOUT FLAVII
Flavii Therapeutics S.L. is a biotechnology company dedicated to developing epigenetic therapies for central nervous system (CNS) disorders that currently lack curative treatment options.
The company was founded in October 2025 as a spin-off from the University of Barcelona (UB), a leading public academic institution renowned for its excellence in teaching, research, and innovation, based in Barcelona.
Vision
We aim to lead the future of epigenetic therapeutics by transforming innovative science into clinical solutions that improve lives and generate lasting social impact.
Flavii focuses its drug development on the following unmeet clinical needs:
· Neurodegenerative diseases
· Neurodevelopmental disorders
Mission
At Flavii Therapeutics, our mission is to develop first-in-class epigenetic therapies that address unmet medical needs in central nervous system (CNS) disorders. We are committed to transforming lives by offering new hope to patients and families affected by conditions with no current cure.
Our values and how we make a difference:
Scientific Excellence
We prioritize rigor, integrity, and deep scientific insight to drive meaningful discoveries.
Purpose-Driven Commitment
Rooted in personal experience, we are committed to developing therapies that truly improve patients’ lives.
Social Responsibility & Ethical Stewardship
We give back to communities and honor our supporters by translating innovation into real-world solutions
Innovation & Strategic Collaboration
We foster innovation through diverse, cross-sector partnerships that accelerate therapeutic breakthroughs.
Impact & Long-Term Value Creation
We aim to generate lasting social, health, and economic value for patients and communities
Patient-Centered Focus
Patients guide everything we do: from research priorities to therapeutic development.
SCIENCE
R&D the core of Flavii
Flavii Therapeutics aims to develop innovative epigenetic therapies for central nervous system disorders. To date, we have identified five promising epigenetic drugs in various stages of preclinical development, with Oxapi-27 being the most advanced, now on the verge of entering regulatory preclinical studies.
TEAM
Our multidisciplinary team is committed to bring our technology into the hands of those who need it the most, the patients. Throughout this amazing journey, we also count with the support of our excellent advisory board.
Dr. Aina Bellver Sanchis, Co-Founder, Board Member and CSO
Prof. Christian Griñán Ferré, Co-Founder, Research advisor & Board Member / Group Leader at the Neuroepilab, University of Barcelona (UB)
Dr. Ariadna Boloix Amenós, Co-Founder, Board Member, CEO and CBO
Contact
We are always ready to help you and answer your questions
Get in touch
info@flaviitherapeutics.com
Faculty of Pharmacy and Food Sciences University of Barcelona
Av. Joan XXIII, 27-31, building A,
08028 – Barcelona, Catalunya (Spain)
At Flavii, we are committed to making epigenetic treatments available for patients suffering from CNS disorders. We strongly believe we can succeed in meaningfully improving the lives of patients and their families.